BCLSI
PHVS icon

Bain Capital Life Sciences Investors’s Pharvaris PHVS Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.5M Hold
2,675,509
– – 5.5% 7
2026
Q1 		$75.6M Sell
2,675,509
-126,572
-5% -$3.38M 6.82% 5
2025
Q4 		$77.8M Sell
2,802,081
-379,194
-12% -$9.13M 5.96% 5
2025
Q3 		$79.4M Sell
3,181,275
-122,106
-4% -$2.71M 5.27% 4
2025
Q2 		$58.1M Hold
3,303,381
– – 7.27% 4
2025
Q1 		$51.9M Hold
3,303,381
– – 7.67% 3
2024
Q4 		$63.3M Hold
3,303,381
– – 7.45% 3
2024
Q3 		$61.2M Hold
3,303,381
– – 6.37% 6
2024
Q2 		$62.1M Hold
3,303,381
– – 6.82% 5
2024
Q1 		$76.3M Sell
3,303,381
-600,938
-15% -$16M 6.14% 6
2023
Q4 		$110M Sell
3,904,319
-880,355
-18% -$17.8M 10.5% 3
2023
Q3 		$99.9M Sell
4,784,674
-84,110
-2% -$1.55M 11.17% 2
2023
Q2 		$73.7M Buy
4,868,784
+1,688,183
+53% +$16.3M 7.59% 4
2023
Q1 		$25.6M Hold
3,180,601
– – 3.2% 11
2022
Q4 		$35.8M Hold
3,180,601
– – 4% 9
2022
Q3 		$24.4M Hold
3,180,601
– – 2.91% 12
2022
Q2 		$70.3M Hold
3,180,601
– – 8.24% 3
2022
Q1 		$57.7M Hold
3,180,601
– – 5.6% 4
2021
Q4 		$45.8M Hold
3,180,601
– – 3.63% 9
2021
Q3 		$56.4M Hold
3,180,601
– – 3.5% 11
2021
Q2 		$59.3M Hold
3,180,601
– – 3.88% 8
2021
Q1 		$89M Buy
+3,180,601
New +$100M 5.04% 6

Other funds holding PHVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bain Capital Life Sciences Investors's PHVS Position: Q2 2026 in Review

Bain Capital Life Sciences Investors held its Pharvaris (PHVS) position steady in Q2 2026 at 2,675,509 shares worth $92.5M. The position accounts for 5.5% of the portfolio, ranked #7.

Bain Capital Life Sciences Investors first reported a position in PHVS in Q1 2021 and has held it in 22 quarters since. The position peaked at $110M in Q4 2023. 125 funds tracked by Wall St. Rank hold PHVS as of Q2 2026.

  • Bain Capital Life Sciences Investors held 2,675,509 shares of Pharvaris worth $92.5M as of Q2 2026.
  • Bain Capital Life Sciences Investors left its Pharvaris share count unchanged in Q2 2026.
  • Pharvaris made up 5.5% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #7 holding.
  • Bain Capital Life Sciences Investors first reported a position in Pharvaris in Q1 2021 and has held it in 22 quarters since.
  • Bain Capital Life Sciences Investors's Pharvaris position peaked at $110M in Q4 2023.
  • 125 funds tracked by Wall St. Rank held Pharvaris as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.